Enoxaparin Prophylaxis Dosing in Adults
For VTE prophylaxis in adults, use enoxaparin 40 mg subcutaneously once daily for hospitalized medical patients and most surgical patients, or 30 mg subcutaneously twice daily for orthopedic surgery patients.
Standard Dosing by Clinical Setting
Hospitalized Medical Patients
- 40 mg subcutaneously once daily 1, 2, 1
- Continue for duration of hospital stay or until fully ambulatory
- This dose was proven effective in reducing VTE from 14.9% to 5.5% compared to placebo (p<0.001) 3
Surgical Patients
Two acceptable regimens 1, 2, 1:
- 40 mg given 10-12 hours preoperatively, then 40 mg once daily postoperatively, OR
- 20 mg given 2-4 hours preoperatively, then 40 mg once daily postoperatively
- Continue for at least 7-10 days; consider extending to 4 weeks in high-risk patients
Orthopedic Surgery (Hip/Knee Arthroplasty)
- 30 mg subcutaneously twice daily 4
- Begin 12 hours before or after surgery
- Continue for 10-14 days, consider extending to 35 days
Outpatient Prophylaxis (Cancer Patients)
- 40 mg subcutaneously once daily 2
- Duration somewhat uncertain; most studies did not assess beyond 6 months
Critical Dose Adjustments
Severe Renal Insufficiency (CrCl <30 mL/min)
Reduce to 30 mg subcutaneously once daily 5, 6. This is the only LMWH with specific FDA-approved dosing for severe renal impairment. Enoxaparin carries a 2-3 fold increased bleeding risk when standard doses are used in severe renal insufficiency 5.
Important caveat: Consider dose reduction even with CrCl 30-50 mL/min, as renal clearance is reduced by 31% in moderate renal impairment 5.
Underweight Patients (<50 kg or BMI <18.5 kg/m²)
The evidence is mixed but favors standard dosing:
- 40 mg once daily appears safe in most underweight patients 7, 8
- Recent data shows no significant difference in bleeding between 30 mg and 40 mg daily in underweight ICU patients 7
- For extremely underweight patients (<40 kg), consider weight-based dosing at 0.5 mg/kg daily with anti-Xa monitoring (target 0.2-0.4 IU/mL) 9
Obese Patients (BMI >30 kg/m²)
Standard 40 mg once daily is insufficient in morbidly obese patients 5. However, specific dosing recommendations vary by institution. The guidelines recommend:
- Each institution should prepare a LMWH dosing algorithm for obese patients 5
- Consider higher doses or twice-daily dosing
- Anti-Xa monitoring may be warranted
Elderly Patients (≥70 years)
- Use standard 40 mg once daily 1, 2, 1
- Exercise caution, particularly if concurrent renal insufficiency exists
- Avoid tinzaparin in elderly patients with renal insufficiency due to increased mortality 5
Timing Considerations with Neuraxial Anesthesia
When epidural or spinal anesthesia is planned 1:
- Do not administer within 10-12 hours before the procedure or catheter removal
- First postoperative dose: 6-8 hours after surgery
- After catheter removal: Wait at least 2 hours before administering enoxaparin
Common Pitfalls to Avoid
Do not use 20 mg daily - this dose was proven ineffective (15% VTE rate vs 14.9% placebo) 3
Do not forget renal function - always check creatinine clearance before initiating standard dosing, as accumulation occurs with CrCl <50 mL/min 5
Do not assume all LMWHs are equivalent in renal disease - only enoxaparin has specific FDA-approved renal dosing adjustments 5
Do not use standard dosing in morbidly obese patients - dalteparin 5000 IU daily was ineffective in patients with BMI ≥40 kg/m² 5
Monitor for HIT - although rare with prophylactic dosing, LMWHs are contraindicated in patients with active HIT 5
The 40 mg once daily dose represents the evidence-based standard that balances efficacy (proven VTE reduction) with safety (acceptable bleeding rates) across most adult hospitalized patients 1, 2, 1, 3.